What are the guidelines for the use of pembrolizumab in treatment of stage IIIa or IIIb non-small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Marvaretta M Stevenson, MD; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print


Pembrolizumab is indicated as first-line monotherapy for patients with stage III NSCLC, who are not candidates for surgical resection or definitive chemoradiation and whose tumor expresses programmed death ligand 1 (PD-L1) with a Tumor Proportion Score (TPS) ≥1%. [28]

  • Pembrolizumab 200 mg IV q3wk or 400 mg IV q6wk; continue until disease progression or unacceptable toxicity (for up to 24 mo)

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!